Normon’s commercial activity is currently structured in five great business areas:
Generic Drugs Division
The Prescription Division is undoubtedly one of Normon’s main pillars. It comprises both brand-name products and generic drugs. Normon was the first laboratory that marketed a generic drug in Spain in 1997.
Nowadays, Normon is the leading pharmaceutical company producing generic drugs in Spain, as we have the largest vade mecum of the market with more than 200 active ingredients marketed in more than 1,000 products. We are present in the most relevant therapeutic areas of the market, including the cardiovascular, central nervous system, digestive, respiratory and oncology fields.
Normon is committed to healthcare professionals through its Prescription Division, which is composed of highly qualified staff. The Company pays special attention to lifelong learning, offering courses and materials of high scientific value, such as the Normon Manual, whose eighth edition is already available.
Normon’s Hospital Division is present in practically all clinics and hospitals in Spain, and offers the widest range of oral and parenteral products used in healthcare facilities.
Normon was the first company to adapt its products for hospital use by manufacturing medication in unit doses, thus facilitating the work of healthcare professionals in the hospital sector.
It has recently consolidated its position as the leading provider of medication to hospitals in Spain. It supplies more than 19% of all hospital medication in the country.
The Dental Division in Normon was established in 1992, when Ultracain, the most prestigious anesthetic within the dentistry field, was first manufactured and marketed.
Currently, Normon has completed its dental anesthesia line with other products, which has led it to be the leader in this sector, with a share close to 60% of the market for dental anesthetics. For the manufacture of these specialties in cartridges (cylindrical vials), Normon has facilities equipped with the latest technology, which in addition to increasing our production capacity, is allowing us to export our products to other countries.
Along with the anesthetic products and the prescription drugs (mainly antibiotics, analgesics and anti-inflammatory drugs), Normon has provided dental professionals with a wide variety of world class products, such as our line of needles and syringes, sutures, dental restorative and printing materials, disinfectants, whiteners, biomaterials, etc.
In an endeavor to enhance our quality of life, adopt healthy habits and prevent disease, self-care has become an extremely important concern of society today. Normon's goal is to meet users’ needs, which together with a new era of hope has made it possible for the company to launch a new OTC Division in 2010, consisting of five product families:
Normo-EFP: medication to relieve the symptoms of minor ailments, such as analgesics, antitussives, antiseptics, etc.
Normovital: food supplements to help maintain or restore vitality.
Normodent: products for a correct dental hygiene.
Normomar: products for a complete nasal care and hygiene.
Normovisión: products for the care of your eyes.
Normocare: products for the care of your health.
Normocalm: products for pain relief and inflammation.
Normopic: insect repellents.
Normogel: hydrogel treatment for burns.
This is the beginning of a new business line that will be increased in the coming future with the launch of new products in this interesting field of self-care and well-being.
Normon has more than 40 years' experience in international business. Laboratorios Normon is present in Europe, Central America, South America, Asia and Africa. Normon's experience in the field of generic drugs and the knowledge acquired throughout more than 30 years in our international activity, has led us to intensify our work in this line of products that are increasingly requested for their lower cost, quality warranty and best service.
The company is currently immersed in an ambitious international expansion project to bring our products to the five continents.
The year 2004 was a key year for Normon's presence in Central America and the Caribbean, where intense work has been done on generic drugs’ registrations, and extensive training has been provided for doctors and pharmacists on bioequivalence studies; this way, Normon is the first company to show concern on this issue. Portugal is another country where Normon is working intensely in the marketing of generic drugs, as well as in the launch of the entire line of dental products. In 2016 Normon received the FDA approval to market its products in the United States.